Meeting
2017 ASCO Annual Meeting
Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.
Authors
Georg A. Bjarnason
Sunnybrook Research Institute, Toronto, ON, Canada
Georg A. Bjarnason , Christian K. Kollmannsberger , Qasim Ahmad , Luca Dezzani , Mohamed Elmeliegy , Jackie Han , Paul D. Nathan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT00720941
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4574)
DOI
10.1200/JCO.2017.35.15_suppl.4574
Abstract #
4574
Poster Bd #
252
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
First Author: Antoine Thiery-Vuillemin
Poster
2017 Genitourinary Cancers Symposium
The SUNPAZ study: Results of an open label, single arm trial to evaluate patients with mRCC treated with everolimus after failure of first line therapy with sunitinib or pazopanib.
First Author: Martin Schostak
Poster
2019 Genitourinary Cancers Symposium
Exploratory endpoints in a FARETES study of the efficacy of testosterone in metastatic renal cell carcinoma (mRCC) patients.
First Author: Ilya Tsimafeyeu
Poster
2019 Genitourinary Cancers Symposium
Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.
First Author: Ernesto Rossi